Cabaletta Bio (CABA) Share-based Compensation (2018 - 2025)
Cabaletta Bio's quarterly Share-based Compensation came in at $4.3 million in Q4 2025, down 21.31% year-on-year from $5.4 million in Q4 2024, and down 26.78% quarter-over-quarter from $5.8 million in Q3 2025.
Cabaletta Bio has reported Share-based Compensation for 8 years, with the latest figure at $4.3 million in Q4 2025.
- For the quarter ending Q4 2025, Share-based Compensation fell 21.31% year-over-year to $4.3 million; the trailing twelve-month figure through Dec 2025 stood at $20.9 million (up 46.64% YoY), and the FY2025 full-year result was $20.9 million, up 7.57% from the prior year.
- Share-based Compensation for Q4 2025 stood at $4.3 million, down from $5.8 million in the prior quarter.
- The five-year high for Share-based Compensation was $5.8 million in Q3 2025, with the low at $1392.0 in Q2 2023.
- Average Share-based Compensation over 5 years is $2.6 million, with a median of $2.1 million recorded in 2022.
- Year-over-year, Share-based Compensation slumped 99.91% in 2023 and surged 186394.25% in 2024.
- Tracing CABA's Share-based Compensation over 5 years: stood at $1.6 million in 2021, then decreased by 1.44% to $1.6 million in 2022, then jumped by 93.35% to $3.1 million in 2023, then jumped by 77.35% to $5.4 million in 2024, then slipped by 21.31% to $4.3 million in 2025.
- The last three Share-based Compensation figures came in at $4.3 million (Q4 2025), $5.8 million (Q3 2025), and $5.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - | 4.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.26 Mn |
| Dec 31, 2025 | 4.26 Mn |
| Sep 30, 2025 | 5.82 Mn |
| Sep 30, 2025 | 5.82 Mn |
| Jun 30, 2025 | 5.71 Mn |
| Jun 30, 2025 | 5.71 Mn |
| Mar 31, 2025 | 5.16 Mn |
| Mar 31, 2025 | 5.16 Mn |
| Dec 31, 2024 | 5.41 Mn |
| Dec 31, 2024 | 5.41 Mn |
| Sep 30, 2024 | 2.48 Mn |
| Sep 30, 2024 | 2.48 Mn |
| Jun 30, 2024 | 2.60 Mn |
| Jun 30, 2024 | 2.60 Mn |
| Mar 31, 2024 | 3.79 Mn |
| Mar 31, 2024 | 3.79 Mn |
| Dec 31, 2023 | 3.05 Mn |
| Dec 31, 2023 | 3.05 Mn |
| Sep 30, 2023 | 1,596.00 |
| Sep 30, 2023 | 1,596.00 |
| Jun 30, 2023 | 1,392.00 |
| Jun 30, 2023 | 1,392.00 |
| Mar 31, 2023 | 2.48 Mn |
| Mar 31, 2023 | 2.48 Mn |
| Dec 31, 2022 | 1.58 Mn |
| Dec 31, 2022 | 1.58 Mn |
| Sep 30, 2022 | 1.73 Mn |
| Sep 30, 2022 | 1.73 Mn |
| Jun 30, 2022 | 857,000.00 |
| Jun 30, 2022 | 857,000.00 |
| Mar 31, 2022 | 1.81 Mn |
| Mar 31, 2022 | 1.81 Mn |
| Dec 31, 2021 | 1.60 Mn |
| Dec 31, 2021 | 1.60 Mn |
| Sep 30, 2021 | 683,000.00 |
| Sep 30, 2021 | 683,000.00 |
| Jun 30, 2021 | 684,000.00 |
| Jun 30, 2021 | 684,000.00 |
| Mar 31, 2021 | 1.31 Mn |
| Mar 31, 2021 | 1.31 Mn |
| Dec 31, 2020 | 1.32 Mn |
| Dec 31, 2020 | 1.32 Mn |
| Sep 30, 2020 | 588,000.00 |
| Sep 30, 2020 | 588,000.00 |
| Jun 30, 2020 | 491,000.00 |
| Jun 30, 2020 | 491,000.00 |
| Mar 31, 2020 | 873,000.00 |
| Mar 31, 2020 | 873,000.00 |
| Dec 31, 2019 | 819,000.00 |
| Dec 31, 2019 | 819,000.00 |
| Sep 30, 2019 | 44,000.00 |
| Sep 30, 2019 | 44,000.00 |
| Jun 30, 2019 | 44,000.00 |
| Jun 30, 2019 | 44,000.00 |
| Mar 31, 2019 | 496,000.00 |
| Mar 31, 2019 | 496,000.00 |
| Dec 31, 2018 | 280,000.00 |
| Dec 31, 2018 | 280,000.00 |
| Sep 30, 2018 | 195,000.00 |
| Sep 30, 2018 | 195,000.00 |